BALLESTRI, Stefano
 Distribuzione geografica
Continente #
NA - Nord America 6.698
AS - Asia 2.584
EU - Europa 2.395
SA - Sud America 348
Continente sconosciuto - Info sul continente non disponibili 86
AF - Africa 51
OC - Oceania 12
Totale 12.174
Nazione #
US - Stati Uniti d'America 6.612
SG - Singapore 836
CN - Cina 648
GB - Regno Unito 603
VN - Vietnam 305
IT - Italia 304
FI - Finlandia 285
HK - Hong Kong 282
BR - Brasile 253
PL - Polonia 243
SE - Svezia 232
DE - Germania 215
BD - Bangladesh 131
RU - Federazione Russa 111
FR - Francia 104
UA - Ucraina 99
TR - Turchia 82
IN - India 59
BG - Bulgaria 48
CA - Canada 43
ID - Indonesia 38
JP - Giappone 38
AR - Argentina 34
KR - Corea 32
LT - Lituania 28
NL - Olanda 25
MX - Messico 20
MY - Malesia 16
ZA - Sudafrica 16
IQ - Iraq 15
PK - Pakistan 15
VE - Venezuela 15
EC - Ecuador 13
ES - Italia 13
PH - Filippine 12
IE - Irlanda 11
CZ - Repubblica Ceca 10
GR - Grecia 10
UZ - Uzbekistan 10
BE - Belgio 9
SA - Arabia Saudita 9
CO - Colombia 8
BO - Bolivia 7
CL - Cile 7
AT - Austria 6
AU - Australia 6
EG - Egitto 6
NP - Nepal 6
NZ - Nuova Zelanda 6
PE - Perù 6
RO - Romania 6
AE - Emirati Arabi Uniti 5
JM - Giamaica 5
KE - Kenya 5
OM - Oman 5
SI - Slovenia 5
AL - Albania 4
DZ - Algeria 4
EU - Europa 4
MA - Marocco 4
SV - El Salvador 4
TH - Thailandia 4
TW - Taiwan 4
CH - Svizzera 3
GT - Guatemala 3
IL - Israele 3
JO - Giordania 3
LB - Libano 3
RS - Serbia 3
TN - Tunisia 3
UY - Uruguay 3
AZ - Azerbaigian 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
HU - Ungheria 2
IR - Iran 2
KG - Kirghizistan 2
KW - Kuwait 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MK - Macedonia 2
NO - Norvegia 2
PT - Portogallo 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
AO - Angola 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EE - Estonia 1
GH - Ghana 1
Totale 12.075
Città #
Fairfield 759
Ashburn 640
Singapore 550
Santa Clara 513
Woodbridge 462
Houston 364
Southend 338
Seattle 337
Chandler 312
Wilmington 301
Hong Kong 278
Helsinki 255
Cambridge 246
Warsaw 241
San Jose 239
Dearborn 192
Ann Arbor 182
Nyköping 165
Jacksonville 137
Beijing 132
New York 123
Council Bluffs 121
London 115
Chicago 112
Hefei 108
Los Angeles 102
Ho Chi Minh City 87
Modena 80
Hanoi 75
The Dalles 56
Sofia 46
Princeton 44
Eugene 43
Izmir 43
Salt Lake City 43
San Diego 43
Lauterbourg 36
Moscow 35
Milan 31
Shanghai 31
Seoul 30
Dallas 29
Buffalo 28
Frankfurt am Main 25
Jakarta 24
São Paulo 24
Tokyo 24
Munich 23
Phoenix 21
Tampa 21
Manchester 19
Elk Grove Village 18
Orem 17
Redwood City 17
Chennai 15
Columbus 14
Da Nang 14
Des Moines 14
Denver 13
San Mateo 13
Amsterdam 12
Haiphong 12
Atlanta 11
Dublin 11
Guangzhou 11
Rome 11
Athens 10
Boardman 10
Dong Ket 10
Kansas City 10
Naples 10
Bremen 9
Florence 9
Kunming 9
Lancaster 9
North Salt Lake 9
Paris 9
Redondo Beach 9
San Francisco 9
Tashkent 9
Biên Hòa 8
Bologna 8
Brno 8
Brussels 8
Jersey City 8
Johannesburg 8
Miano 8
Nanjing 8
Padova 8
Palisades Park 8
Schiffdorf 8
Baghdad 7
Brooklyn 7
Buenos Aires 7
Falls Church 7
Kuala Lumpur 7
Mexico City 7
Norwalk 7
Poplar 7
Rio de Janeiro 7
Totale 8.770
Nome #
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 496
Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study 443
Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes 431
Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease. 395
Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis 390
Review article: the metabolic syndrome and non-alcoholic fatty liver disease 386
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk 374
Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma 370
Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. 369
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis 367
Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? 361
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-Evidence from three different disease models: NAFLD, HCV and HIV 339
Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis 327
Nonalcoholic fatty liver disease and aging: epidemiology to management 322
Clinical relevance of liver histopathology and different histological classifications of NASH in adults 317
Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. 315
A critical appraisal of the use of ultrasound in hepatic steatosis 305
Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease? 301
Magnetic resonance for quantitative assessment of liver steatosis: a new potential tool to monitor antiretroviral-drug-related toxicities. 289
Is cholangiocarcinoma another complication of insulin resistance: A report of three cases 288
Treatment of atherogenic liver based on the pathogenesis of nonalcoholic Fatty liver disease: a novel approach to reduce cardiovascular risk? 280
Alcohol and Steatosis: The Japanese Paradox 275
Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases 274
Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. 273
Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen 273
A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? 272
Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia? 245
Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? 242
Non-alcoholic Fatty Liver Disease: a HR-MAS analysis 233
Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications 229
Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis c virus infection—liver: The “Musketeer” in the spotlight 229
Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: Chance tetrad or association by necessity? 211
Nanoparticles: potential toxins for the organism and the kidney ? 200
Gli enzimi epatobiliari nella diagnostica clinica delle Epatopatie. 200
Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent? 199
The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology 199
Hypervascular Retroperitoneal Mass in a Patient with Fever and Leucocytosis - Contrast-Enhanced Ultrasonographic Findings in a Case of Inflammatory Malignant Fibrous Histiocytoma 195
The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans 192
Sex Differences in NAFLD: State of the Art and Identification of Research Gaps 187
The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment 178
NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk 167
Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease 131
Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease 105
Totale 12.174
Categoria #
all - tutte 45.696
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.696


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022782 34 95 77 31 17 37 48 29 102 75 172 65
2022/2023827 82 126 62 76 87 116 16 79 96 8 34 45
2023/2024457 15 25 42 24 97 61 21 39 10 4 56 63
2024/20251.754 48 21 36 121 361 252 143 135 178 71 167 221
2025/20264.164 221 108 241 411 652 562 602 177 430 302 222 236
2026/202798 98 0 0 0 0 0 0 0 0 0 0 0
Totale 12.174